- Home
- SBGI vs GHRS Comparison
SBGI vs GHRS Comparison
Compare SBGI & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBGI | GHRS |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | Ireland |
| Employees | 7100 | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 947.2M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SBGI | GHRS |
|---|---|---|
| Price | $14.01 | $21.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $22.00 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 424.5K | 255.2K |
| Earning Date | 04-30-2026 | 05-01-2026 |
| Dividend Yield | ★ 6.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $3,169,000,000.00 | N/A |
| Revenue This Year | $12.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $50.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.89 | $10.67 |
| 52 Week High | $17.88 | $24.66 |
Technical Indicators
Market Signals| Indicator | SBGI | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 39.59 | 60.68 |
| Support Level | $13.34 | $12.41 |
| Resistance Level | $15.48 | $22.88 |
| Average True Range (ATR) | 0.59 | 1.33 |
| MACD | -0.18 | -0.07 |
| Stochastic Oscillator | 12.73 | 67.96 |
Price Performance
Historical ComparisonAbout SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.